Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01669603 · ClinicalTrials.gov registry record · NA

Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)

A NA study, sponsored by University of Virginia.

Completed
Registry status
NA
Development phase
789
Enrollment target

NCT01669603: Completed NA study, sponsored by University of Virginia.

NCT01669603 is a NA study that has completed, run by University of Virginia. The registered enrollment target is 789 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01669603, a NA study, has completed, sponsored by University of Virginia.

COMPLETED
Registry status
NA
Development phase
789 participants
Enrollment target

Study Summary

The study is designed to assess the effect of ingestion of a probiotic on innate and adaptive host responses to rhinovirus infection.

Primary Outcome

Nasal lavage will be performed to collect and measure IL-8.

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Bifidobacterium lactis Bl-04
  • BIOLOGICAL Rhinovirus

Trial Details

FieldValue
Enrollment Target 789 participants
Start Date 2012-08
Est. Completion 2016-06
Phase NA
University of Virginia

449 total trials

What the finished NCT01669603 record still lists

NCT01669603 is an interventional study that assigns participants to a tested intervention. The registered 789 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (44% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT01669603 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01669603 about?

NCT01669603 is a clinical study titled "Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)". The study is designed to assess the effect of ingestion of a probiotic on innate and adaptive host responses to rhinovirus infection.

What is the current status of trial NCT01669603?

This trial is currently completed. It is a NA study. The enrollment target is 789 participants. The study started on 2012-08. Estimated completion is 2016-06.

What interventions are being tested in trial NCT01669603?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Bifidobacterium lactis Bl-04 (DIETARY_SUPPLEMENT), Rhinovirus (BIOLOGICAL).

Who is sponsoring clinical trial NCT01669603?

This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01669603's enrollment target sits among peer trials

789 141st of 2000 higher than 1,860 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04967989 · 790 participants · Phase 3

    Clarifying the Optimal Application of SLT Therapy Trial

  • NCT06162611 · 790 participants · Phase 4

    Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo

  • NCT06488781 · 787 participants · Phase 2

    Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0

  • NCT06876649 · 787 participants · Phase 4

    A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01669603, the US trial registry maintained by the National Library of Medicine. NCT01669603 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.